Tryp Therapeutics Inc. Stock OTC Markets
Equities
TRYPF
CA89854F1062
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0476 USD | -2.76% | +32.50% | +39.88% |
Mar. 08 | Tryp Therapeutics Inc. announced that it has received AUD 3.39 million in funding | CI |
Feb. 05 | Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 5.79M 4.23M |
---|---|---|---|---|---|
Net income 2024 * | -5M -3.65M | Net income 2025 * | -5M -3.65M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2
x | P/E ratio 2025 * |
-3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.27% |
1 day | -2.76% | ||
1 week | +32.50% | ||
Current month | +171.02% | ||
1 month | +171.02% | ||
3 months | +56.91% | ||
6 months | -13.27% | ||
Current year | +39.88% |
Managers | Title | Age | Since |
---|---|---|---|
Jason Carroll
CEO | Chief Executive Officer | - | 23-09-30 |
James Kuo
FOU | Founder | 58 | 19-09-23 |
James O’Neill
DFI | Director of Finance/CFO | 64 | 22-09-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Kuo
FOU | Founder | 58 | 19-09-23 |
Peter Molloy
PRN | Corporate Officer/Principal | 52 | 20-09-24 |
Director/Board Member | - | 22-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.0476 | -2.76% | 40,413 |
24-04-26 | 0.049 | +4.26% | 399,838 |
24-04-25 | 0.047 | +9.56% | 138,717 |
24-04-24 | 0.0429 | +16.42% | 143,998 |
24-04-23 | 0.0368 | +2.50% | 1,596 |
Delayed Quote OTC Markets, April 29, 2024 at 02:06 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- TRYP Stock
- TRYPF Stock